Monday, June 5, 2023

ASCO 2023: Day 1- Cervical Cancer, HIPEC, Antibody Drug Conjugates in Gyn Cancers

Note: Due to the number of Tweets embedded in this post the page may take some time to load.

This year I attended #ASCO23 virtually. Some of the sessions were available live but some were on-demand usually a day later. Many of the Tweets I will share in the next few posts were from those I follow who attended those sessions in person. 

Friday, June 2,2023

Clinical Science Symposium  

Cervical Cancer 

An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC):  A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).       Abtract LBA 5511


 Read more about the above study at https://www.cancer.net/blog/2023-06/asco-annual-meeting-2023-less-extensive-hysterectomy-effective-early-cervical-cancer-and-adding?cmpid=ks_cancernet_net_awareness_sno_facebook_all__glob_060223____aware_photo-text_ 

 

 

 HIPEC in Ovarian Cancer

Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up. (Sonke  abstract 5509) 
Median follow up of 10.1 years. "One hundred and eight patients (87.8%) in the surgery group have died as compared to 100 patients (82.0%) in the surgery-plus-HIPEC group.Median recurrence-free survival was 10.7 months in the surgery group compared to 14.3 months in the surgery-plus-HIPEC group (HR, 0.63; 95% confidence interval [CI], 0.48-0.83; stratified P<0.001). This study provides the first long-term survival analysis of HIPEC in ovarian cancer and confirms the benefit of HIPEC in patients with primary stage III epithelial ovarian cancer undergoing interval cytoreductive surgery. "                                   Overall survival 44.9 with HIPEC versus 33.3 no HIPEC. 
Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial. (abstract 5510)
"The CHIPOR multicentric randomized phase III trial (NCT01376752), conducted in 31 institutions, enrolled patients with a first platinum-sensitive relapse (platinum-free interval of ≥6 months) of EOC. Patients were treated with 6 cycles of platinum and taxane based CT ± bevacizumab, and those amenable to a complete cytoreductive surgery at the end of CT were enrolled and randomly assigned to receive HIPEC (cisplatin 75 mg/m² at 41°C for 60 min) or not. HIPEC significantly improves OS and peritoneal PFS of women with first platinum-sensitive relapse of EOC treated with second-line platinum-based CT followed by secondary complete cytoreductive surgery."
 
 
Education Session 
 Antibody Drug Conjugates: New Opportunities in Gynecologic Cancer

 


 




Dee

Every Day is a Blessing!

Posted by at
Labels: , , , , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)